Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma

Click to increase image sizeClick to decrease image size Disclosure statementE.D., S.A., and C.Y.H report that there are no competing interests to declare. M. L. is a consultant for EUSA Pharma and Oncopeptides. T.M. receives research funding from Janssen, Amgen, and Sanofi. T.M. is a consultant for GlaxoSmithKline. J.W. is a consultant for Adaptive Biotechnologies, Teneobio, Sanofi, and Amgen. A.C. receives research funding from Caelum. N.S. receives research funding from Bluebird Bio, BMS/Celgene, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and Teneobio. N.S. is a consultant for Amgen, CareDx, CSL Behring, GSK, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, and Sanofi. S.W.W receives research funding from Bristol-Myers Squib, Fortis, Janssen, Genentech, GSK, and Caelum. S.W.W. is on the advisory board for Sanofi and Telix. S.W.W. is a consultant for Amgen.Additional informationFundingThis study was supported by the University of California, San Francisco School of Medicine (Summer Explore Research Grant) and the UCSF Multiple Myeloma Translational Initiative.